During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...

Menopause marks the end of a woman’s childbearing years, but it doesn’t mark the end of the need for a particular screening ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Human papillomavirus (HPV) is necessary for the development of cervical carcinoma, and incorporation ... management and implemented in cervical cancer screening programmes. In this article we ...

Cervical cancer has been designated an AIDS-defining ... Relationship of Human Papillomavirus to Cervical Dysplasia and Carcinoma. MedGenMed 1(2), 1999. [formerly published in Medscape Women's ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Project ECHO HPV Vaccination Series receives support in honor of UNR Med Alumnus John M. Erickson, M.D.

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

and compressive cervical mass. The therapeutic strategy involves a multimodal approach that improves local control and survival. We present three cases of anaplastic thyroid carcinoma: two men, aged ...